Show Me the Data^®: Managing Clinical Challenges in Advanced EGFR Mutation–Positive NSCLC

Release Date: July 8, 2021
Expiration Date: July 8, 2022

Activity Overview

In this on-demand archived webcast challenging clinical cases in frontline management of EGFR-mutated NSCLC is discussed, as experts substantiate their treatment choices with the appropriate supporting evidence at each decision point. The rapid progress in molecular testing and therapeutic options for patients with advanced, EGFR mutation-positive non-small cell lung cancer (NSCLC) can make it difficult to identify optimal treatment approaches. Throughout this program,  you will gains insights on how experts in the field of NSCLC management leverage key data sets to support decision-making vis-à-vis when to initiate therapy, how to appropriately sequence or switch therapies, how to monitor the patient, and how to apply best practices for adverse event management. The evidence-based expert discussion in this program will aid you in applying the latest updates in cutting edge care to your patients with NSCLC.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Lilly USA, LLC.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
 

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists who treat patients with NSCLC. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of NSCLC are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss current and emerging molecular testing approaches to optimize therapy for patients with metastatic NSCLC
• Apply key clinical data related to initial therapy for patients with EGFR mutation–positive NSCLC
• Evaluate the rationale for combination therapies in the setting of advanced NSCLC and EGFR mutations
• Describe interventions for patients with EGFR mutation–positive NSCLC and CNS involvement and/or therapy-related adverse events

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

David R. Gandara, MD
Professor of Medicine Emeritus
Division of Hematology/Oncology
Director of Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant Research Support: Amgen, AstraZeneca, Genentech, Merck; Consultant: AstraZeneca, Roche-Genentech, Guardant Health, Inivata Limited, IO Biotech, Lilly, Merck, Novartis, OncoCyte

Heather M,Wakelee, MD
Professor of Medicine (Oncology)
Chief, Division of Oncology
Stanford University Medical Center
Deputy Director, Stanford Cancer Institute
Stanford, CA

Disclosures: Grant Research Support: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, Bristol Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Merck, Novartis, Pharmacyclics, Seagen, Xcovery; Consultant: AstraZenca, Daiichi Sankyo, Blueprint Medicines, Helsinn Therapeutics, Genentech/Roche, Merck, Mirati Therapeutics.

Edward B.Garon, MD, MS
Professor, Department of Medicine, Division of Hematology/Oncology
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosures: Grant Research Support: AstraZeneca, Bristol Myers Squibb, Dynavax Technologies, Eli Lilly, EMD Serono, Genentech, Iovance Biotherapeutics; Merck, Mirati Therapeutics, Neon, Novartis; Consultant: ABL Bio, Boehringer-Ingelheim, Bristol Myers Squibb, Dracen Pharmaceuticals, EMD Serono, Eisai, GlaxoSmithKline, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio Therapeutics

Lecia C.Sequist, MD, MPH
Assistant Professor
UCSF Helen Diller Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research: AstraZeneca.

Collin Blakely MD, PhD
Associate Professor of Medicine
Leukemia Service
Director of CLL Program
Division of Hematology/Oncology
Columbia University Medical Center
New York, NY

Disclosures: Grant Research: AbbVie, AstraZeneca, BeiGene, Genentech, Juno Pharmaceuticals, Loxo Oncology, MingSight Pharmaceuticals, Octapharma, Oncternal Therapeutics, TG Therapeutics; Consultant: AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Janssen, Pharmacyclics.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.